Suven Life Sciences Ltd has secured three product patents, one each from Canada, China and India corresponding to the new chemical entities (NCEs).
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and were being developed as therapeutic agents, the Hyderabad-based company said in a release issued on Friday.
They were useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention Deficient Hyperactivity Disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.